China PMI Falls Into Contraction as Manufacturing, Services Weaken in July 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Gold Price Rallies as Fed Holds Rates, Middle East Tensions Boost Safe-Haven Demand 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
South Korea’s KOSPI Soars as Samsung, SK Hynix Rebound on Microsoft-Fueled AI Rally 
World game at war: why some European nations have threatened a World Cup boycott 
Dollar Posts Worst Monthly Loss Since April as Fed Uncertainty and Yen Intervention Shake FX Markets 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Trump-Backed Russia Sanctions Bill Faces House Hurdles Over Tariff Powers 
US Stocks Slide as Fed Holds Rates, AI Chip Selloff Deepens and Oil Prices Surge 
Oil Prices Ease After Sharp Rally as Trump Warns of More Action Against Iran 
U.S. Treasury Joins Japan in Yen Intervention as Currency Nears 40-Year Lows 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
China PMI Contracts in July as Weak Demand and Typhoons Weigh on Economy 
Bristol Myers Squibb has been sued for $6. 4 billion for allegedly delaying a cancer drug. In the new lawsuit, it was claimed that the American multinational pharmaceutical company headquartered in New York improperly held up the development of a medicine for the treatment of non-Hodgkin's lymphoma.
The allegation against the pharma company
According to Reuters, it was alleged that Bristol Myers Squibb deliberately delayed the development so it can avoid paying $6.4 billion to Celgene Corp. shareholders. Bristol Myers acquired this drug manufacturing company in 2019.
Based on the complaint that was filed at the Manhattan federal court on Thursday, June 3, the company would have owed the said amount if it had received the approval from the U.S. Food and Drug Administration for specified deadlines for three drugs that Celgene had been developing.
In the filing, it was stated that the pharmaceutical company failed to use contractually required "diligent efforts" to get the FDA’s approval for the cancer drug called Breyanzi before the set deadline of Dec. 31, 2020. Now, with no approval before the deadline, the company was excused from paying the sum to Celgene.
It was reported that the lawsuit was filed by the UMB Bank NA, which is acting as a trustee for Celgene’s former shareholders. Bristol-Myers acquired Celgene under a $80.3 billion deal that was signed in November 2019.
Bristol Myers Squibb accused of misconduct
The former shareholders think that Bristol Myers did not exert efforts to beat the deadline when it was supposed to get the FDA’s approval for Breyanzi. They are suspecting that the company did this deliberately to avoid paying them, so they are accusing Bristol Myers of “blatant misconduct,” as per Fierce Pharma.
Finally, the case against Bristol Myers was recorded under 1:21-cv-04897 in the U.S. District Court-Southern New York. The shareholders that were represented by UMB Bank NA sued the pharma firm for breaching the CVR agreement through its failure to exert efforts to secure the needed approval from the FDA.
